News | August 14, 2009

Lantheus Seeks New Mo-99 Supplies, Solutions to Isotope Crisis

August 14, 2009 - Lantheus Medical Imaging will continue to allocate its Mo-99 supply to serve as many people as possible, said the company today in response to the statement issued by AECL regarding the extended shutdown of the NRU reactor Aug. 12.

Lantheus is collaborating with its supply partners and key customers to address the ongoing global isotope shortage of molybdenum-99 (Mo-99), the parent isotope of technetium-99m (Tc-99m) used in its TechneLite generators, as a result of the prolonged NRU reactor shutdown in Canada and the current shutdown of the High Flux Reactor (HFR) in the Netherlands.

In an effort to actively explore options to obtain additional Mo-99, the company announced new Mo-99 supply agreements with NTP Radioisotopes (Pty) Ltd., a subsidiary of the Nuclear Energy Corp. of South Africa (NECSA), the National Institute for Radioelements (IRE), Belgium, and the Australian Nuclear Science and Technology Organisation (ANSTO) as a supplier for low-enriched uranium (LEU) Mo-99 in the North America, respectively, to manufacture and supply us with an ongoing volume of Mo-99.  These agreements demonstrate our continued commitment to investing in a supply chain diversification strategy to address the limited and fragile global Mo-99 supply chain.  Additionally, the company has significantly increased production of thallium 201 in our cyclotrons on site which are operating at full capacity to meet the demand for this alternate cardiac imaging agent during the Mo-99 shortage.

Lantheus recently endorsed the American Medical Isotopes Production Act sponsored by Representatives Edward J. Markey (D-Mass.), chairman of the House Energy and Commerce Committee Subcommittee on Energy and the Environment, and Fred Upton (R-Mich.), the ranking member of the subcommittee, which seeks to ensure that a reliable supply of critical medical isotopes is produced in the United States as soon as possible.

For more information: www.lantheus.com

Related Content

PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Vital Unveils Newest Vitrea Advanced Visualization Release at RSNA 2017
Technology | Advanced Visualization | December 04, 2017
Vital Images unveiled the newest version of Vitrea Advanced Visualization software, the cornerstone of its imaging...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
Netherlands Cancer Institute Exploring Molecular Imaging Technology for Prostate Cancer Surgery
News | Molecular Imaging | October 26, 2017
The Netherlands Cancer Institute (NKI) announced it has received funding from the Dutch Cancer Society (KWF...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Biodex Unveils Atomlab 500 Dose Calibrator and Wipe Test Counter
Technology | Nuclear Imaging | October 19, 2017
Biodex Medical Systems announced the full release of the Atomlab Dose Calibrator and Wipe Test Counter to the market...
ASNC and ASE Team Up to Expand ImageGuide Registry
News | Cardiovascular Ultrasound | October 12, 2017
The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) jointly announced...
MR Solutions Showcases Multimodality MRI Solutions on Two Continents
News | Magnetic Resonance Imaging (MRI) | October 11, 2017
October 11, 2017 — MR Solutions took their cryogen-free preclinical multimodality...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
Overlay Init